玻璃体内注射雷尼珠单抗辅助23号玻璃体切除联合ahmed青光眼瓣膜植入术治疗新生血管性青光眼

中国实用眼科杂志 Pub Date : 2017-06-10 DOI:10.3760/CMA.J.ISSN.1006-4443.2017.06.018

Jie Guo, Qiuming Li

{"title":"玻璃体内注射雷尼珠单抗辅助23号玻璃体切除联合ahmed青光眼瓣膜植入术治疗新生血管性青光眼","authors":"Jie Guo, Qiuming Li","doi":"10.3760/CMA.J.ISSN.1006-4443.2017.06.018","DOIUrl":null,"url":null,"abstract":"Objective \nTo observe the effects of intravitreal Ranibizumab injection (IVR) as an Adjuvant combined 23-gauge vitrectomy (23G-TSV) and Ahmed glaucoma valve (AGV) implantation for Neovascular Glaucoma (NVG). \n \n \nMethods \nTwenty-five patients (25 eyes) of NVG with vitreous hemorrhage (VH) underwent IVR combined with 23G-TSV and AGV implantation. \n \n \nResults \nThe neovascularization of iris and anterior chamber angle in all patients completely or partly disappeared one week after IVR. At last visit, BCVA was improved compared with pre-operative BCVA; the IOP was significantly decreased after surgery; The surgical success rate was 88.0%. No serious complication occurred. \n \n \nConclusions \nFor stage Ⅲ NVG with VH, IVR as an adjuvant combined 23G-TSV and AGV implantation is safe and effective. \n \n \nKey words: \nGlaucoma; Neovascular; Implants; Ahmed; Vitrectomy; 23G; Ranibizumab","PeriodicalId":10236,"journal":{"name":"中国实用眼科杂志","volume":"36 1","pages":"617-621"},"PeriodicalIF":0.0000,"publicationDate":"2017-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Intravitreal ranibizumab injection as an adjuvant combined 23-gauge vitrectomy and ahmed glaucoma valve implantation in the treatment of neovascular glaucoma\",\"authors\":\"Jie Guo, Qiuming Li\",\"doi\":\"10.3760/CMA.J.ISSN.1006-4443.2017.06.018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective \\nTo observe the effects of intravitreal Ranibizumab injection (IVR) as an Adjuvant combined 23-gauge vitrectomy (23G-TSV) and Ahmed glaucoma valve (AGV) implantation for Neovascular Glaucoma (NVG). \\n \\n \\nMethods \\nTwenty-five patients (25 eyes) of NVG with vitreous hemorrhage (VH) underwent IVR combined with 23G-TSV and AGV implantation. \\n \\n \\nResults \\nThe neovascularization of iris and anterior chamber angle in all patients completely or partly disappeared one week after IVR. At last visit, BCVA was improved compared with pre-operative BCVA; the IOP was significantly decreased after surgery; The surgical success rate was 88.0%. No serious complication occurred. \\n \\n \\nConclusions \\nFor stage Ⅲ NVG with VH, IVR as an adjuvant combined 23G-TSV and AGV implantation is safe and effective. \\n \\n \\nKey words: \\nGlaucoma; Neovascular; Implants; Ahmed; Vitrectomy; 23G; Ranibizumab\",\"PeriodicalId\":10236,\"journal\":{\"name\":\"中国实用眼科杂志\",\"volume\":\"36 1\",\"pages\":\"617-621\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国实用眼科杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1006-4443.2017.06.018\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实用眼科杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1006-4443.2017.06.018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

目的观察玻璃体内注射雷尼单抗(IVR)辅助23号玻璃体切除术(23G-TSV)联合Ahmed青光眼瓣膜(AGV)植入术治疗新生血管性青光眼(NVG)的疗效。方法25例(25眼)NVG合并玻璃体出血(VH)行IVR联合23G-TSV和AGV植入术。结果所有患者术后1周虹膜及前房角新生血管全部或部分消失。末次访视BCVA较术前有所改善;术后IOP明显降低;手术成功率为88.0%。无严重并发症发生。结论对于Ⅲ期NVG合并VH, IVR作为辅助23G-TSV联合AGV植入是安全有效的。关键词:青光眼;新生血管性;植入物;艾哈迈德;玻璃体切除术;23 g;之初

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Intravitreal ranibizumab injection as an adjuvant combined 23-gauge vitrectomy and ahmed glaucoma valve implantation in the treatment of neovascular glaucoma

Objective To observe the effects of intravitreal Ranibizumab injection (IVR) as an Adjuvant combined 23-gauge vitrectomy (23G-TSV) and Ahmed glaucoma valve (AGV) implantation for Neovascular Glaucoma (NVG). Methods Twenty-five patients (25 eyes) of NVG with vitreous hemorrhage (VH) underwent IVR combined with 23G-TSV and AGV implantation. Results The neovascularization of iris and anterior chamber angle in all patients completely or partly disappeared one week after IVR. At last visit, BCVA was improved compared with pre-operative BCVA; the IOP was significantly decreased after surgery; The surgical success rate was 88.0%. No serious complication occurred. Conclusions For stage Ⅲ NVG with VH, IVR as an adjuvant combined 23G-TSV and AGV implantation is safe and effective. Key words: Glaucoma; Neovascular; Implants; Ahmed; Vitrectomy; 23G; Ranibizumab

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中国实用眼科杂志

自引率

0.00%

发文量

9101

期刊介绍： China Practical Ophthalmology was founded in May 1983. It is supervised by the National Health Commission of the People's Republic of China, sponsored by the Chinese Medical Association and China Medical University, and publicly distributed at home and abroad. It is a national-level excellent core academic journal of comprehensive ophthalmology and a series of journals of the Chinese Medical Association. China Practical Ophthalmology aims to guide and improve the theoretical level and actual clinical diagnosis and treatment ability of frontline ophthalmologists in my country. It is characterized by close integration with clinical practice, and timely publishes academic articles and scientific research results with high practical value to clinicians, so that readers can understand and use them, improve the theoretical level and diagnosis and treatment ability of ophthalmologists, help and support their innovative development, and is deeply welcomed and loved by ophthalmologists and readers.